Trial Profile

Assessment of the effects of telmisalthan and olmethaltan on inflammation and oxidative stress in patients on maintenance hemodialysis.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Mar 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olmesartan medoxomil (Primary) ; Telmisartan (Primary)
Indications Secondary hypertension
Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

01 Feb 2012 Results published in Clinical and Experimental Hypertension (CEH).
25 Jan 2010 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
25 Jan 2010 Actual initiation date (Jan 2010) added as reported by University Hospital Medical Information Network - Japan record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com